Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented ...

A comprehensive eight-year study examining audiological outcomes of newborns screened for congenital cytomegalovirus (cCMV) ...

One of the goals of Co-Diagnostics, Inc., a molecular diagnostic company which developed PCR testing for COVID-19, ...

Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024;Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 ...

BD (Becton, Dickinson and Company) (NYSE: BDX) a leading global medical technology company, today announced it has received U ...

As winter brings a rise in coughs, colds, and fevers, it’s often hard to tell if it’s just a seasonal viral, the flu, or ...

By leveraging advanced Polymerase Chain Reaction (PCR) technology with streamlined testing for a broad range of gastrointestinal (GI) bacterial pathogens from a single stool swab sample, the panels ...

Co-Diagnostics (CODX) announced the formation of a newly organized, artificial intelligence business unit, led by Chief Technology & AI Officer ...

Victoria is ramping up its biosecurity defences against H5N1 bird flu, with new federal support to boost emergency preparedness and rapid response ...

A start-up should always have a “plan B” to provide a critical safety net. A considerable and expensive amount of redundant lab equipment can sit idle if that pivot arises and prompts a significant ...

Summary: In patients who remained in remission beyond month 3 (M3), including those with deep MRD-negative remission and no post obe-cel SCT, ongoing CAR T-cell persistence at M3, measured by droplet ...